{"DataElement":{"publicId":"2674599","version":"1","preferredName":"Myelodysplastic Syndrome Chronic Myeloproliferative Disorder Chronic Myelomonocytic Leukemia Disease or Disorder Transplantation Timepoint Remission Status","preferredDefinition":"Information related to the disease status of myelodysplastic syndrome, chronic myeloproliferative disorder or chronic myelomonocytic leukemia at the time of transplant.","longName":"MDS_MPS_CMML_STAT","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2676474","version":"1","preferredName":"Myelodysplastic Syndrome Chronic Myeloproliferative Disorder Chronic Myelomonocytic Leukemia Disease or Disorder Transplantation Timepoint","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001)_Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults._A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001)_Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._The grafting of tissues from one individual to another or place to place within a single individual._A specific point in the time continuum, including those established relative to an event.","longName":"MDS_MPS_CMML_TRN_TM","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2760526","version":"1","preferredName":"MDS Chronic Myeloproliferative Disorder Chronic Myelomonocytic Leukemia Disease or Disorder","preferredDefinition":"Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001) -- 2003:Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults.  -- 2003:A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001) -- 2003:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","longName":"C3247:C4345:C3178:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chronic Myelomonocytic Leukemia","conceptCode":"C3178","definition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"501BEE23-66BF-4A2A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-20","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-06-20","modifiedBy":"ONEDATA","dateModified":"2008-06-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2716694","version":"1","preferredName":"Transplantation Timepoint","preferredDefinition":"The grafting of tissues from one individual to another or place to place within a single individual.:A specific point in the time continuum, including those established relative to an event.","longName":"C15342:C68568","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Timepoint","conceptCode":"C68568","definition":"A specific point in the time continuum, including those established relative to an event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41CDDE79-E081-680C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-12-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-12-21","modifiedBy":"ONEDATA","dateModified":"2007-12-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3938FAD5-BADE-0F0C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2672741","version":"1","preferredName":"Myelodysplastic Syndrome Chronic Myeloproliferative Disorder Chronic Myelomonocytic Leukemia Remission Status","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001)_Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults._A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001)_An abatement in intensity or degree (as in the manifestations of a disease)._A condition or state at a particular time.","longName":"MDS_MPS_CMML_STAT","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"51","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Prog / worse","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"2559908","version":"1","preferredName":"Progressive Disease","longName":"2559908","preferredDefinition":"Cancer that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B711-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeDescription":"Manually Curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A7E742A-24E5-2C1F-E044-0003BA3F9857","beginDate":"2007-09-19","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-19","modifiedBy":"ALEYR","dateModified":"2007-09-19","deletedIndicator":"No"},{"value":"NR - no response","valueDescription":"Without Response","ValueMeaning":{"publicId":"2683158","version":"1","preferredName":"Without Response","longName":"2683158","preferredDefinition":"Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): In medicine, an improvement related to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A7E742A-24F4-2C1F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-19","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A7E742A-250D-2C1F-E044-0003BA3F9857","beginDate":"2007-09-19","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-19","modifiedBy":"ALEYR","dateModified":"2007-09-19","deletedIndicator":"No"},{"value":"CR","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"2577915","version":"1","preferredName":"Complete Remission","longName":"2577915","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD68-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A7E742A-2543-2C1F-E044-0003BA3F9857","beginDate":"2007-09-19","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-19","modifiedBy":"ALEYR","dateModified":"2007-09-19","deletedIndicator":"No"},{"value":"Treated with chemotherapy","valueDescription":"Chemotherapy","ValueMeaning":{"publicId":"2558484","version":"1","preferredName":"Chemotherapy","longName":"2558484","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term is used to describe any therapy involving the use of chemical-based agents, it is particularly used to refer to the use of chemical-based agents to treat cancer. Antineoplastic chemotherapy works by arresting or killing the growth and spread of cancer cells. Chemotherapy may also include agents that enhance immune function or alter hormonal activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B181-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"COOPERM","dateModified":"2014-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"384AD24E-C0E5-288F-E044-0003BA3F9857","beginDate":"2007-08-22","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-22","modifiedBy":"ALEYR","dateModified":"2007-08-22","deletedIndicator":"No"},{"value":"Relapse after complete response","valueDescription":"Relapse CR","ValueMeaning":{"publicId":"2672742","version":"1","preferredName":"Relapse CR","longName":"2672742","preferredDefinition":"The return of signs and symptoms of cancer after a period of improvement.: The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapse","conceptCode":"C18265","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37BF2CAF-5D55-73A1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"37BF2CAF-5D6E-73A1-E044-0003BA3F9857","beginDate":"2007-08-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-15","modifiedBy":"ALEYR","dateModified":"2007-08-15","deletedIndicator":"No"},{"value":"Supportive care or treatment without chemotherapy","valueDescription":"Supportive Care Without Chemotherapy","ValueMeaning":{"publicId":"2683161","version":"1","preferredName":"Supportive Care Without Chemotherapy","longName":"2683161","preferredDefinition":"Supportive care is that which helps the patient and their family to cope with cancer and treatment of it from pre-diagnosis, through the process of diagnosis and treatment, to cure, continuing illness or death and into bereavement. It helps the patient to maximise the benefits of treatment and to live as well as possible with the effects of the disease. There is considerable overlap between supportive and palliative care in terms of need.: Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Supportive Care","conceptCode":"C15747","definition":"Supportive care is that which helps the patient and their family to cope with cancer and treatment of it from pre-diagnosis, through the process of diagnosis and treatment, to cure, continuing illness or death and into bereavement. It helps the patient to maximize the benefits of treatment and to live as well as possible with the effects of the disease. Supportive therapy may provide a patient with friendship, encouragement, practical advice such as access to community resources or how to develop a more active social life, vocational counseling, suggestions for minimizing friction with family members, and, above all, hope that the life of the patient may be improved. In all situations, supportive therapy involves the teaching of such life skills as managing medication, learning to socialize, handling finances, and getting a job.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A7E742A-2553-2C1F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-19","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"50AB336C-6665-4726-E044-0003BA3F9857","beginDate":"2007-08-15","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-06-27","modifiedBy":"NYCHM","dateModified":"2008-06-27","deletedIndicator":"No"},{"value":"Improvement but no CR","valueDescription":"No CR Better","ValueMeaning":{"publicId":"2761979","version":"1","preferredName":"No CR Better","longName":"2761979","preferredDefinition":"The non-affirmative response to a question.: The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.: In an improved condition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Better","conceptCode":"C71685","definition":"In an improved condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"50F73170-416E-4D58-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-07-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"50F73170-4187-4D58-E044-0003BA3F9857","beginDate":"2007-09-19","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-07-01","modifiedBy":"ALEYR","dateModified":"2008-07-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2760528","version":"1","preferredName":"MDS Chronic Myeloproliferative Disorder Chronic Myelomonocytic Leukemia Remission Status","preferredDefinition":"Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001) -- 2003:Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults.  -- 2003:A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001) -- 2003:An abatement in intensity or degree (as in the manifestations of a disease).:A condition or state at a particular time.","longName":"C3247:C4345:C3178:C18246:C2568","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Chronic Myelomonocytic Leukemia","conceptCode":"C3178","definition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"501BEE23-66D9-4A2A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-20","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-06-20","modifiedBy":"ONEDATA","dateModified":"2008-06-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"37BF2C2D-58FF-67BB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-15","modifiedBy":"COOPERM","dateModified":"2014-12-09","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"pre_ted_mds_mps_cmml_stat","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:diseaseStatusCode","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the status of MDS/MP","type":"Preferred Question Text","description":"What was the status of MDS/MPS/CMML at transplantation?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping for CDE:2674599","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis.value = \"Myelodysplastic Syndrome\" AND PerformedDiagnosis > PerformedSubstanceAdministration > DefinedSubstranceAdministration.nameCode = \"Administer Hematopoietic Stem Cell Product {Transplantation}\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"384B648C-21C2-1050-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-22","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-22","modifiedBy":"KUMMEROA","dateModified":"2021-04-30","changeDescription":". .1/8/14mn-added Bridg info. 2021-4-30 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}